News Release

Personal psychedelic use may be common among psychedelic therapists

Peer-Reviewed Publication

Mary Ann Liebert, Inc./Genetic Engineering News

Psychedelic Medicine

image: This journal provides a vital resource for clinicians and patients alike who are invested in the potential efficacy of psychedelic drugs currently undergoing research in preclinical and clinical studies as an alternative or supplement to traditionally manufactured pharmaceuticals to treat depression, anxiety, addiction, demoralization, and other mental health conditions view more 

Credit: Mary Ann Liebert, Inc., publishers

Whether personal use of psychedelics is appropriate among psychedelic therapists, a new study finds that it may be common. The study is published in the peer-reviewed journal Psychedelic Medicine. Click here to read the article now.

Experiential learning is common in psychotherapy. Psychedelic therapy is a practice that uses psychedelics such as psilocybin as an adjunct to psychotherapy. Some contend that having personal experience with psychedelics is essential to understanding the effects of these substances and being an effective psychedelic therapist, although there are no data that support this contention, psychedelics remain Schedule I controlled substances, and use outside of approved research settings is illegal in the United States, United Kingdom, and elsewhere

Jacob Aday, PhD, from the University of California, San Francisco, and coauthors surveyed psychedelic therapists involved in a trial of psilocybin to treat major depressive disorder. The vast majority of the respondents reported personal experience using psychedelic compounds.  

About the Journal

Psychedelic Medicine is the first peer-reviewed journal to publish original research papers on every aspect of psychedelic medicine, including basic science, clinical, and translational research, as well as medical applications. This journal provides a vital resource for clinicians and patients alike who are invested in the potential efficacy of psychedelic drugs currently undergoing research in preclinical and clinical studies as an alternative or supplement to traditionally manufactured pharmaceuticals to treat depression, anxiety, addiction, demoralization, and other mental health conditions. Visit the Psychedelic Medicine website to learn more.

About the Publisher

Mary Ann Liebert, Inc., publishers is known for establishing authoritative peer-reviewed journals in many promising areas of science and biomedical research. A complete list of the firm’s more than 100 journals and books is available on the Mary Ann Liebert, Inc., publishers website.

 


Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.